Clinuvel Pharmaceuticals Limited (ASX: CUV)
Australia
· Delayed Price · Currency is AUD 11.79
-0.15 (-1.26%)
Dec 20, 2024, 4:10 PM AEST
Clinuvel Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Operating Revenue | 81.22 | 81.22 | 72.18 | 60 | 42.6 | 26.31 | Upgrade
|
| Other Revenue | 6.96 | 6.96 | 6.14 | 5.72 | 5.72 | 6.26 | Upgrade
|
| Revenue | 88.18 | 88.18 | 78.32 | 65.72 | 48.32 | 32.57 | Upgrade
|
| Revenue Growth (YoY) | 12.59% | 12.59% | 19.17% | 36.02% | 48.37% | 4.89% | Upgrade
|
| Cost of Revenue | 7.73 | 7.73 | 7.52 | 9.25 | 4.17 | 7.3 | Upgrade
|
| Gross Profit | 80.45 | 80.45 | 70.8 | 56.47 | 44.15 | 25.26 | Upgrade
|
| Selling, General & Admin | 22.84 | 22.84 | 15.65 | 13.03 | 11.57 | 12.23 | Upgrade
|
| Research & Development | 2.35 | 2.35 | 1.27 | 1.23 | 0.55 | 0.34 | Upgrade
|
| Other Operating Expenses | -0.56 | -0.56 | -0.02 | -0.22 | - | - | Upgrade
|
| Operating Expenses | 31.88 | 31.88 | 26.67 | 20.92 | 15.58 | 13.01 | Upgrade
|
| Operating Income | 48.57 | 48.57 | 44.13 | 35.55 | 28.57 | 12.25 | Upgrade
|
| Interest Expense | -4.45 | -4.45 | -3.19 | -2.27 | -1.62 | -2.05 | Upgrade
|
| Interest & Investment Income | 7.32 | 7.32 | 3.91 | 0.44 | - | 0.56 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.76 | -0.76 | 0.74 | 0.6 | -1.37 | 0.65 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | 0 | Upgrade
|
| EBT Excluding Unusual Items | 50.68 | 50.68 | 45.58 | 34.32 | 25.58 | 11.41 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.13 | 0.13 | Upgrade
|
| Pretax Income | 50.68 | 50.68 | 45.58 | 34.32 | 25.71 | 11.54 | Upgrade
|
| Income Tax Expense | 15.04 | 15.04 | 14.97 | 13.44 | 0.98 | -3.51 | Upgrade
|
| Earnings From Continuing Operations | 35.64 | 35.64 | 30.6 | 20.88 | 24.73 | 15.05 | Upgrade
|
| Net Income | 35.64 | 35.64 | 30.6 | 20.88 | 24.73 | 15.05 | Upgrade
|
| Net Income to Common | 35.64 | 35.64 | 30.6 | 20.88 | 24.73 | 15.05 | Upgrade
|
| Net Income Growth | 16.44% | 16.44% | 46.58% | -15.57% | 64.29% | -17.00% | Upgrade
|
| Shares Outstanding (Basic) | 50 | 50 | 49 | 49 | 49 | 49 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 51 | 52 | 52 | 51 | 50 | Upgrade
|
| Shares Change (YoY) | -1.52% | -1.52% | 0.08% | 1.26% | 1.33% | 1.73% | Upgrade
|
| EPS (Basic) | 0.72 | 0.72 | 0.62 | 0.42 | 0.50 | 0.31 | Upgrade
|
| EPS (Diluted) | 0.70 | 0.70 | 0.59 | 0.40 | 0.48 | 0.30 | Upgrade
|
| EPS Growth | 18.11% | 18.11% | 46.65% | -16.74% | 62.42% | -18.58% | Upgrade
|
| Free Cash Flow | 31.48 | 31.48 | 35.88 | 39.44 | 18.41 | 13.3 | Upgrade
|
| Free Cash Flow Per Share | 0.62 | 0.62 | 0.69 | 0.76 | 0.36 | 0.26 | Upgrade
|
| Dividend Per Share | 0.050 | 0.050 | 0.050 | 0.040 | 0.025 | 0.025 | Upgrade
|
| Dividend Growth | 0% | 0% | 25.00% | 60.00% | 0% | 0% | Upgrade
|
| Gross Margin | 91.23% | 91.23% | 90.40% | 85.92% | 91.36% | 77.58% | Upgrade
|
| Operating Margin | 55.08% | 55.08% | 56.34% | 54.09% | 59.12% | 37.62% | Upgrade
|
| Profit Margin | 40.41% | 40.41% | 39.08% | 31.77% | 51.18% | 46.22% | Upgrade
|
| Free Cash Flow Margin | 35.70% | 35.70% | 45.82% | 60.01% | 38.10% | 40.84% | Upgrade
|
| EBITDA | 49.32 | 49.32 | 44.52 | 35.97 | 29.07 | 12.42 | Upgrade
|
| EBITDA Margin | 55.93% | 55.93% | 56.85% | 54.74% | 60.16% | 38.12% | Upgrade
|
| D&A For EBITDA | 0.75 | 0.75 | 0.4 | 0.43 | 0.5 | 0.16 | Upgrade
|
| EBIT | 48.57 | 48.57 | 44.13 | 35.55 | 28.57 | 12.25 | Upgrade
|
| EBIT Margin | 55.08% | 55.08% | 56.34% | 54.09% | 59.12% | 37.62% | Upgrade
|
| Effective Tax Rate | 29.68% | 29.68% | 32.85% | 39.17% | 3.83% | - | Upgrade
|
| Revenue as Reported | 95.31 | 95.31 | 82.99 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.